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1.1 KETOGENIC DIET 
 
1.1.1. Definition and mechanisms of action 
 
The ketogenic diet (KD) is a high-fat, low-carbohydrate, and normal-protein diet which 
increases the production of the ketone bodies (i.e., b-hydroxybutyrate and 
acetoacetate) providing an alternative fuel source for the brain.  
The ketogenic diet (KD) is a nonpharmacologic treatment used worldwide for children 
with intractable epilepsy (Tagliabue et al, 1997; Stafstrom & Rho, 2004; Kossoff & 
McGrogan, 2005; Freeman et al., 2007). 
Despite myriad anticonvulsants available and in various stages of development, there 
are thousands of children and adults with epilepsy worldwide still refractory to 
treatment and not candidates for epilepsy surgery. Many of these patients will now 
turn to dietary therapies such as the ketogenic diet.  
 
Although numerous studies have shown the clinical efficacy of the KD, the 
mechanisms underlying its antiseizure effect remain only partially elucidated.  
During starvation, the metabolic priority is to provide sufficient glucose or alternative 
fuel to the brain and other tissues (such as red blood cells) that are absolutely 
dependent on glucose consumption. The dominant metabolic processes are the 
mobilization of triacylglycerols in adipose tissue and gluconeogenesis in the liver. The 
liver obtains energy for its own needs by oxidising fatty acids released from adipose 
tissue and produces large amounts of ketone bodies (acetate, acetoacetate and b-
hydroxybutyrate), from acetyl CoA. 
Acetyl CoA is markedly increased because the citric acid cycle is unable to oxidise all 
the acetyl units generated by the degradation of fatty acids. Gluconeogenesis depletes 
the supply of oxaloacetate, which is essential for the entry of acetyl CoA into the citric 
acid cycle (Fig. 1) (Bertoli S et al., 2005). 
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Fig.1 TCA cycle (from Bertoli S et al, 2005) 
 
Brain consumes about 120 g of carbohydrates daily, which corresponds to an energy 
input of about 420 kcal, accounting for some 60% of the utilisation of glucose by the 
whole body in the resting state. Much of the energy, is used to power transport 
mechanisms that maintain the Na+-K+ membrane potential required for the 
transmission of the nerve impulses and to synthesise neurotransmitters and their 
receptors to propagate nerve impulses (Siegel et al, 1998). 
Ketone bodies are metabolized by b-hydroxybutyrate dehydrogenase, acetoacetate-
succinyl-CoA transferase and acetoacetyl-CoA-thiolase enzymes which are present in 
brain tissue in sufficient amounts to convert them into acyl-CoA and to feed them into 
the tricarboxylic acid cycle at a sufficient rate to satisfy the metabolic demands of the 
brain . 
Consequently, the brain begins to consume appreciable amounts of ketone bodies 
becoming its major fuels in substitution of glucose. With the progression of fasting, 
proteins begin to be increasingly degraded, and when protein losses are greater 25% of 
body stores, death inevitably results from a loss of multiple organ functions. 
Ketogenic diet induces a metabolic condition similar to a “prolonged starvation” but it 
provides an adequate amount of energy and protein to maintain intact the 
triacylglycerol stores and to limit protein breakdown, turning brain metabolism 
towards ketone bodies as the source of energy supply. 
Significant utilisation of ketone bodies by the brain occurs, however, in the neonatal 
period. The newborn infant tends to be hypoglycemic but at the beginning of nursing 
he becomes ketotic because of the high fat content of the mother's milk. 
The increment in plasmatic concentration of ketone bodies and their utilisation as brain 
fuel was considered the mechanism of action of KD on seizure control since 1930s. 
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Wilder (1921) postulated that the anticonvulsant effects of KD were caused by the 
“sedative ”effects of acetoacetate. Recent evidence shows that cultured astrocytes are 
also ketogenic cells and the ketone bodies produced may be used in situ as substrates 
for neuronal metabolism, and may exert prosurvival actions per se by acting as cellular 
substrates, thereby preserving neuronal synaptic function and structural stability 
(Guzman, 2004). These findings support the notion of Likhodii and coworkers (2003) 
that recently investigated the spectrum of anticonvulsant activity of acetone in animal 
seizure models and suggested that the elevation of brain acetone may account for the 
efficacy of the KD in intractable epilepsy. Acetone has been showed to suppress 
experimental seizures but considerable more data are needed before the “acetone 
hypothesis” will be proved. 
 
Numerous other hypotheses have been suggested regarding the anti-epileptic action of 
the KD. All of them refer to changes induced by the KD in metabolic pathways, cell or 
extra-cellular milieu which may decrease excitability and dampen epileptic discharge. 
 
KD shifts substrates utilization towards fatty acids resulting in an increment of ATP to 
ADP ratio and in the brain as showed by De Vivo et al.  (1978). These observations 
suggest that KD may work through an increase of energy reserve in the brain. A link 
between ATP production and excitability is the ATPsensitive potassium channels that 
have been demonstrated in a variety of cells including neurons. The opening of these 
channels result in cell hyperpolarization and determines a decrease in basal 
excitability.  
Moreover, KD could induce an alteration of lipid composition of cell’s membrane 
resulting from the high fat content of the diet. The consequences of such a change 
range from increased fluidity to alteration in the insertion of receptor and channel 
molecules. 
 
It has been reported (Erecinska M et al, 1996) that beta-hydroxibutyrate (BHB) or 
acetoacetate raises synaptosomal glutamate content and also increases GABA 
concentrations (and its rate of synthesis), the most important inhibitory 
neurotransmitter. 
 
Elevated PUFA may represent a key anticonvulsant mechanism of the KD. Children on 
the high fat ketogenic diet are usually maintained in a state of mild energy restriction, 
which probably contributes to the elevation in plasma free fatty acids. Free fatty acids 
increased 2.2-fold on the KD, with significant elevations in most polyunsaturated fatty 
acids (arachidonate increased 1.6 – 2.9-fold and docosahexaenoate increased 1.5-4.0-
fold). the observed increase in serum (and presumably brain) PUFA was within 
therapeutic range established in animal model and may therefore be implicated in the 
seizure-controlling effect of the KD in humans. 
 8 
 
Also cholesterol is involved in the synthesis of neurosteroids which have been shown 
to have significant activity at GABA receptors (Kokate TG et al, 1994). 
Schwartzkroin (1999) describes how KD could act both on pH and hydration of the 
brain. Therefore changes in both factors need to be considered among possible 
mechanisms. pH changes affect neuronal excitability both directy (altering the efficacy 
of synaptic transmission) and indirectly influencing glial cell function. Glial glycogen 
metabolism results in the excretion of lactate (an energy source which can be used by 
neurons) and which induce extracellular acidosis. During KD treatment the glia turn to 
glycogen metabolism releasing lactate and potentially lowering extracellular pH with 
consequent reduction in neuronal excitability. It is known that seizures can be induced 
by overhydration and dehydration has antiseizure consequences (Rosen, 1991). These 
effects of changing water balance are due, at least in part, to the fact that when the 
extracellular space is made hypoosmotic water moves into neurons (and glia) and 
causes them to swell. Cell swelling is associated with enhanced neuronal syncrony, a 
key feature of  epileptiform activity. Blockade of swelling leads to a larger ECS volume 
which in turn may decrease the effectiveness of synchronizing mechanisms. There are 
no studies documenting changes in hydration in KD-fed children but we do not know 
how water is distributed in the brains of these children. 
 
Finally, there is the possibility that KD may lead to changes in gene expression that can 
modulate brain excitability and epileptogenicity. Leite et al (2004) has recently 
investigated  in astrocyte cultures, the effect induced by b-hydroxy-butyrate, upon 
S100B secretion, a calciumbinding protein expressed and secreted by astrocytes with 
neurotrophic activity and a possible role in epileptogenesis. 
One hour after b-hydroxy-butyrate administration changes in astrocyte morphology 
and increment in the extracellular content of S100B was observed resulting in a 
reduction of neuronal excitability. 
 
1.1.2. Indications to the use of KD 
 
The ketogenic diet has been used in patients with a variety of types of seizures and 
epilepsy syndromes (see Table 1).  The diet is the treatment of choice for two distinct 
disorders of brain energy metabolism: GLUT1 deficiency syndrome (Klepper & 
Leiendecker, 2007) and pyruvate dehydrogenase deficiency (PDHD) (Wexler et al., 
1997). In GLUT1 deficiency syndrome, glucose transport across the blood-brain barrier 
is impaired resulting in seizures, developmental delay, and a complex movement 
disorder. 
In PDHD, a severe mitochondrial disease with lactic acidosis and severe impairment, 
pyruvate cannot be metabolized into acetyl-CoA (Wexler et al., 1997). In both 
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disorders, the KD provides ketones that bypass the metabolic defect and serve as an 
alternative fuel to the brain. 
The KD has also been described as particularly useful for certain epilepsy and genetic 
syndromes as well. Myoclonic epilepsies, including severe myoclonic epilepsy of 
infancy (Dravet Syndrome) and myoclonic-astatic epilepsy, as described by Doose 
(Oguni et al., 2002; Laux et al., 2004; Caraballo et al., 2005, 2006; Kilaru & Bergqvist, 
2007; Korff et al., 2007) appear to respond well to the KD. The KD can be beneficial in 
infants with West  syndrome who are refractory to corticosteroids and other 
medications (Kossoff et al., 2002b; Eun et al., 2006). 
The only seizure type that might not have an early, dramatic response (defined as 
patients who became seizure free within 2 weeks of their ketogenic diet admission and 
remained seizure free afterward for ≥6 months) is complex partial seizures, although 
many patients with partial-onset seizures have excellent results (similar in one series to 
those with generalized epilepsy), and some eventually become seizure-free. The 
ketogenic diet did not stop disease progression in patients with Lafora body disease 
(Cardinali et al., 2006). 
 
 
(from “Optimal clinical management of children receiving the ketogenic diet: 
Recommendations of the International Ketogenic Diet Study Group”) 
 
The KD is contraindicated in several specific disorders (Table 2). The metabolic 
adaptation to the KD involves a shift from use of carbohydrates to lipids as the 
primary energy source. As such, a patient with a disorder of fat metabolism might 
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develop a severe deterioration in the setting of fasting or a KD. Therefore, before 
initiating the KD, a child must be screened for disorders of fatty acid transport and 
oxidation. 
Long-chain fatty acids are transported across the mitochondrial membrane by 
carnitine, facilitated by carnitine palmitoyltransferase (CPT) I and II and carnitine 
translocase (Tein, 2002). Once in the mitochondrion, fatty acids are b-oxidized to two 
carbon units of acetyl-CoA that can then enter the tricarboxylic acid cycle and be 
utilized for energy production or ketone body formation. An inborn metabolic error at 
any point along this pathway can lead to a devastating catabolic crisis (i.e., coma, 
death) in a patient fasted or placed on a KD. Deficiency of pyruvate carboxylase, a 
mitochondrial enzyme that catalyzes the conversion of pyruvate to oxaloacetate, will 
impair tricarboxylic acid cycle function and energy production in patients on the KD. 
Finally, the KD is contraindicated inporphyria, a disorder of heme biosynthesis in 
which there is deficient porphobilinogen deaminase; the lack of carbohydrates in the 
KD can exacerbate acute intermittent porphyria. 
 
 
(from “Optimal clinical management of children receiving the ketogenic diet: 
Recommendations of the International Ketogenic Diet Study Group”) 
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1.1.3 Initiation of KD 
A clinic visit prior to initiation of the KD is necessary and recommended.  
The goals of this visit are to identify the seizure type, rule out metabolic disorders that 
are contraindications to the diet, and evaluate for complicating factors (presence of 
kidney stones, dyslipidemia, liver disease, failure to thrive, gastroesophageal reflux, 
poor oral intake, constipation, cardiomyopathy, and chronic metabolic acidosis). 
Before starting the diet, it is crucial to also discuss psychosocial issues inherent in the 
KD. The physician should ensure that the parent or caregiver understands their 
involvement in administering the KD to their child, specifically the importance of strict 
adherence to the diet, avoidance of carbohydrates, need for multivitamin and mineral 
supplementation, and awareness of potential adverse effects. 
It is important for the ketogenic team to thoroughly discuss parental expectations in 
advance of KD initiation to ensure its success. The expected length of time on the KD if 
successful is often a concern that the family wishes to discuss prior to starting the KD 
and a minimum of 3 months (to allow for potential improvement to occur) should be 
suggested. The family should know what challenges they may face both short and 
long-term, such as possible nausea, vomiting, behavioral outbursts, and various other 
medical complications, and how to address these issues if they arise. 
A complete nutritional evaluation is recommended (baseline weight, height, and ideal 
weight for stature, Body mass index (BMI), nutrition intake history: 7-day food record, 
food preferences, allergies, aversions, and intolerances).  
In our Centre (International Center for the Assessment of Nutritional Status - DeFENS, 
University of Milan) we complete this evaluation with the skinfold thickness measures, 
with the assessment of resting energy expenditure by indirect calorimetry and the 
assessment of body composition (fat mass and fat free mass) and bone mineral density 
by dual x-ray absorbtiometry. We perform also an ultrasound evaluation of adipose 
tissue (sub cutaneous and visceral) and an hepatic and renal ultrasound at basal 
evaluation and every 6-12 months. 
A laboratory evaluation is necessary: complete blood count with platelets, electrolytes 
to include serum bicarbonate, total protein, calcium, zinc, selenium, magnesium, and 
phosphate, serum liver and kidney tests (including albumin, AST, ALT, blood urea 
nitrogen, creatinine), fasting lipid profile, basal glucose and insulin, glycated 
hemoglobin, pre-albumin, tranferrin and ferritin, uric acid, serum acylcarnitine profile, 
urinalysis, urine calcium and creatinine.  
 12 
 
1.1.4 Diet composition 
The dietician and physician determine the ketogenic ratio that will be used, and the 
caloric and fluid contents of the patient’s diet.  
In the classic KD, fat is a LCT and obtained primarily from standard foods, protein is 
based on minimum requirements for growth, and carbohydrates are restricted. MCT 
oils yield more ketones per kilocalorie of energy than their long chain counterparts; 
they are absorbed more efficiently and carried directly to the liver. This increased 
ketogenic potential means less total fat is needed in the MCT diet, thus allowing 
inclusion of more carbohydrate and protein. Data from studies 20 years apart now 
suggest no difference in efficacy between the two diets if applied appropriately in a 
calculated fashion (Schwartz et al., 1989; Neal et al., 2008). There may be some 
differences in tolerability but this did not reach statistical significance in a recent 
randomized controlled trial with direct comparison between the two (Neal et al., 2008). 
The classic KD is calculated in a ratio of grams of fat to grams of protein plus 
carbohydrate. The most common ratio is 4 g of fat to 1 g of protein plus carbohydrate 
(described as ‘‘4:1’’). This means that 90% of the energy comes from fat and 10% from 
protein and carbohydrate combined. Sometimes it is necessary to provide the KD at a 
lower ratio to increase protein or carbohydrate intake. There is some evidence that a 
4:1 ratio, when used at initiation, may be more advantageous for the first 3 months. 
Calories are typically restricted to 80%–90% of the daily recommendations for age; 
however, this has never been shown in patients to be beneficial (Vaisleib et al., 2004). 
Similarly, fluid restriction to 90% is also based on historical use of the diet rather than 
on scientific evidence. 
The traditional MCT diet comprises 60% energy from MCT. This level of MCT can 
cause gastrointestinal discomfort in some children, with reports of abdominal cramps, 
diarrhea, and vomiting. For this reason, a modified MCT diet was developed, using 
30% energy from MCT, with an additional 30% energy from long chain fat. 
The KD may be delivered as an all-liquid, formula-based diet (Kossoff et al., 2004a; 
Hosain et al., 2005) for use in infants who have not yet transitioned to solid foods and 
for individuals fed enterally.  
The KD may also be easily administered to enterally fed children. As expected, 
enterally (including gastrostomy and jejunostomy) fed children demonstrate very high 
compliance rates, exceeding those in most solid food KD series, and efficacy is also 
high. Prescription of a formula-based KD is generally simpler for dietitians to calculate, 
requires less education of families and caregivers, and due to the ease of delivery of an 
all-liquid KD, ketosis is easily maintained as errors are less common. 
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The traditional method of initiating the KD involves a period of fasting, with no 
carbohydrate-containing fluids provided, and serum glucose monitored periodically 
(Freeman et al., 2006).  
The duration of fasting varies from 12 h to ‘‘when urine ketones are large,’’ which can 
be longer than 48 h. Children should not be fasted longer than 72 h. The meals are then 
typically advanced daily in one-third caloric intervals until full calorie meals are 
tolerated, while keeping the KD ratio constant. 
However, there is now retrospective (Kim et al., 2004) and prospective data indicating 
that fasting is not necessary for achievement of ketosis, and that gradual initiation 
protocols offer the same seizure control at 3 months with significant lower frequency 
and severity of initiation related side effects (Bergqvist et al., 2005).  
The main reasons for inpatient initiation include safety (management of acute medical 
side effects) and education of care providers.  In select situations, the KD can also be 
started as an outpatient. The potential advantages of an outpatient, gradual KD 
initiation include less stress for the child, no absence from the home for the care  
providers, and significantly reduced costs associated with hospitalization. 
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1.1.5 Medications and the KD 
The KD is traditionally used in patients who have failed to respond to anticonvulsant 
medications.  
At present, there are no data supporting any significant pharmacodynamic interactions 
between anticonvulsant drugs and the KD. That is, no particular combination of 
anticonvulsants and the KD have been shown to yield either greater or less efficacy in 
terms of seizure protection at this time. Serum levels of commonly used anticonvulsant 
agents, when corrected for changes in dose and weight (i.e., plasma concentration in 
relation to the dose per kilogram of body weight per day), do not appear to be altered 
by the KD (Dahlin et al., 2006).  
There is a historical perception that valproic acid should not be used together with the 
KD. This stems from the concerns for idiosyncratic side effects of valproic acid (i.e., 
hepatotoxicity) and for the fact that this medication is a short-chain fatty acid. 
Clinicians have generally feared that enhanced fatty acid oxidation, a consequence of 
using the high-fat KD, might increase the risk of hepatotoxicity. Despite such fears, 
recent clinical evidence supports the safe use of valproic acid and the KD (Lyczkowski 
et al., 2005).  
The KD is also known to cause a transient but often clinically asymptomatic metabolic 
acidosis. Adding the KD to an existing regimen of carbonic anhydrase inhibitors 
(topiramate and zonisamide) may in fact worsen preexisting metabolic acidosis, but 
the greatest decreases in serum bicarbonate levels occur early after initiation of the 
diet. It is recommended that bicarbonate levels should be monitored carefully, 
especially when receiving these anticonvulsants, and that bicarbonate supplements be 
given when patients are clinically symptomatic (vomiting, lethargy). 
Discontinuing medications is often a major goal of the KD and typically advised after 
several months of success. However, there is evidence that anticonvulsants can be 
reduced successfully even during the first month of the KD (Kossoff et al., 2004b). 
Clinicians should be mindful that formulations of any drugs, including 
nonanticonvulsants, contain carbohydrates or sugars as additives, and should seek 
alternatives whenever possible. 
 
1.1.6 Diet supplementation 
Due to the limited quantities of fruits, vegetables, enriched grains, and foods 
containing calcium on the KD, supplementation is essential, especially for B vitamins, 
vitamin D and calcium. Additional supplementation (e.g., zinc, selenium, magnesium, 
phosphorus) was suggested.  
There is no evidence for the empiric use of antacids, laxatives, or carnitine with the KD. 
Oral citrates appear to be preventative for kidney stones, but its empiric use has not 
yet been established as beneficial. 
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1.1.7 Follow up 
The child on the KD should be seen regularly for follow-up evaluation by both 
dietitian and neurologist familiar with the KD. At discharge, the parents should be 
given specific contact phone numbers and e-mail addresses for the KD team, especially 
the dietitian. The child should be seen initially at least every 3 months after hospital 
discharge with follow-up contact in the interim, especially if expected urinary ketosis 
is not maintained. After 1 year on the KD, visits can be spaced out to every 6 months 
with phone contact in the interim.  
The most common way to measure adherence to the ketogenic diet regimen is urine 
ketones (specifically, β-hydroxybutyrate, and acetoacetate), an easy and relatively cost-
effective indicator of ketosis. Routine urine ketosis evaluation by parents is 
recommended several times per week. Serum levels might correlate with an 
anticonvulsant effect somewhat better than urine. Ketonemia and ketonuria 
(specifically measuring β-hydroxybutyrate and acetoacetate) therefore, probably serve 
as better indicators of adherence than efficacy. It is reasonable to obtain serum BOH in 
clinical situations where urine ketosis does not correlate with expected seizure control 
(e.g., absent urinary ketosis despite seizure freedom or large urinary ketosis in the 
setting of worsening seizures). 
In addition to a complete examination, including accurate growth parameters such as 
weight and height and complete nutritional assessment (see the first evaluation), 
laboratory studies are recommended. Special attention is given to serum albumin and 
total protein concentration to ensure the KD is providing enough protein and calories. 
Fasting cholesterol and triglyceride levels typically rise and should be monitored.   
While receiving the KD, there needs to be ongoing nutritional support and 
management. Caloric intake and growth parameters should be reviewed at least every 
3 months for the first year on the KD to ensure appropriate weight gain for age and 
length. Infants under 1 year of age should be monitored more frequently to prevent 
growth disturbance (Vining et al., 2002). If a child is overly hungry or not eating their 
meals, calories should be adjusted accordingly.  
The ketogenic ratio and percentage MCT oil for the MCT diet may also be adjusted 
upwards in the case of decreased ketosis and loss of seizure control, and lowered in  
situations of diet intolerability, severe dyslipidemia, poor linear growth, or excessive 
ketosis resulting in lethargy.   
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1.1.8 Side effects 
Metabolic abnormalities are relatively minor side effects of the KD and include 
hyperuricemia (2%–26%), hypocalcemia (2%), hypomagnesemia (5%), decreased amino 
acid levels and acidosis (2%–5%), hypercholesterolemia (14%–59%), (Chesney et al., 
1999; Kwiterovich et al., 2003; Kang et al., 2004).  
Gastrointestinal symptoms including vomiting, constipation, diarrhea, and abdominal 
pain occur in 12%–50% of children (Kang et al., 2004).  
Renal calculi occur in 3%–7% of children on the KD (Furth et al., 2000; Sampath et al., 
2007).  
Growth (height and weight) may be impaired, an effect most noticed in younger 
children (Vining et al., 2002; Liu et al., 2003). 
 
1.1.9 KD discontinuation  
 
Consideration should be given to discontinue the KD after 3 months if unsuccessful, 
and 2 years if completely successful, but longer diet durations are necessary for GLUT-
1 and PDHD and may be perfectly appropriate based on individual responses for 
intractable epilepsy. 
Prior to diet discontinuation in seizure-free children, a routine EEG and review of 
clinical data should be performed to counsel families regarding recurrence risk, which 
is 20% overall.  
Children with an epileptiform EEG, abnormal MRI, and tuberous sclerosis complex are 
at higher risk. During discontinuation, the group generally recommends a gradual 
wean over 2–3 months as outlined above, unless an urgent discontinuation of the diet 
is indicated. 
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1.2 PHYSIOLOGY OF FASTING AND KETOGENESIS  
 
The classic model of whole-body metabolism is the human starve-feed cycle, which is 
composed of four global nutritional states: 1) well fed, 2) early fasting, 3) prolonged 
fasting (or starvation), 4) early re-fed. Despite biochemical differences associated with 
each state, all four states are guided by two general principles. Firstly, the human body 
must contain adequate levels of energy to sustain obligate and facultative glucose  
metabolizing tissues. This is particularly important for the central nervous system 
(CNS) because protein-bound fatty acids are unable to cross the blood-brain barrier, 
and the CNS requires between 20% to 50% m of resting metabolic energy. Secondly, 
the human body must retain endogenous protein in order to sustain healthy structural 
and functional physiologic capacity. Of these four global nutritional states, the most 
relevant model for LCKD whole-body metabolism is the metabolism of prolonged 
fasting (Westman et al, 2003). 
 
1.2.1 Prolonged fasting model  
 
During fasting in humans, blood glucose levels are sustained by the breakdown of 
glycogen in liver and muscle and de novo production of endogenous glucose 
(“gluconeogenesis”), primarily from muscle amino acids (Exton et al, 1972). 
Concurrent hepatic generation of ketone bodies supplements glycogenolysis and 
gluconeogenesis to produce energy-yielding substrates for glucose-dependent tissue. 
Therefore, generation of ketone bodies in fasting humans is critical to providing an 
alternative fuel to glucose (Ruderman NB et al, 1974; Owen OE et al, 1967) while also 
avoiding muscle breakdown  (Owen OE et al, 1967; Veech RL et al, 2001). 
 
1.2.2 Fatty acids and ketogenesis from fat  
 
The main fuel produced by an LCKD would logically be fatty acids derived from 
exogenous dietary fat or endogenous adipose tissue. The average respiratory quotient 
associated with an LCKD is approximately  0.70, indicating the use of fatty acids 
primarily (van den Berg B et al, 1994). In addition, serum free fatty acids are higher on 
an LCKD compared with a conventional diet (Phinney SD et al , 1983; Bisshop PH et al, 
2000).  
Although most energy is derived from fatty acids, ketone bodies increase in 
importance as a substitute for glucose. The term ketone bodies (KB) refers to three 
metabolites: acetoacetate, β-hydroxybutyrate, and acetone. Whereas acetone is 
primarily an excretory product, the other KB are dimers of acetyl coenzyme A (CoA) 
and, therefore, serve as transportable forms of energy. During prolonged fasting, fatty 
acids are generated from the breakdown of stored triglyceride in adipocytes (lipolysis) 
(Cahill GF Jr et al, 1970). On an LCKD, the fatty acids are derived from dietary fat, or 
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adipose tissue if the diet does not meet the daily caloric requirement. Free fatty acids 
are delivered to the liver for conversion to KB. KB then exit the liver to provide energy 
to all cells with mitochondria. Within a cell, KB are converted to acetyl CoA for 
generation of ATP via the tricarboxylic acid cycle and oxidative phosphorylation. 
 
Although usually viewed as a response to fasting, the synthesis of KB can also be 
stimulated by a marked reduction of carbohydrate (Klein S et al, 1992). Reducing 
carbohydrate and protein intake leads to a reduced serum insulin level, which, in turn, 
increases the serum glucagon level. The insulin/glucagon (I/G) ratio is a key 
determinant of lipolysis, glycogenolysis, and gluconeogenesis  (Bollen M et al, 1998; 
Pilkis SJ et al, 1992). A high I/G ratio induces lipid and glycogen production via 
insulin-mediated influx of glucose, whereas a low I/G ratio induces glucagon-mediated 
lipolysis. 
 
1.2.3 Gluconeogenesis from protein 
 
Gluconeogenesis refers to the production of glucose from amino acids (“glucogenic 
amino acids”), glycerol, and lactate when glucose is in demand but dietary sources are 
limited (Neely JR et al, 1974). For example, during prolonged fasting or during an 
LCKD there is a reduction in glucose supply, which initiates compensatory 
gluconeogenic mechanisms to sustain glucose-dependent tissue (Gerich JE et al., 2001). 
However, unlike prolonged fasting, during which endogenous glucogenic amino acids 
(muscle) are used for glucose production, the source of glucogenic amino acids on an 
LCKD is dietary protein (Fig. 1). As minimal protein supplementation (1 to 1.5 g of 
protein/kg/d) is necessary to attain nitrogen balance during prolonged fasting, protein 
intake at this level associated with the LCKD may sustain positive nitrogen balance 
and preserve muscle mass (Hoffer W et al, 1984). 
Another substrate for gluconeogenesis is glycerol from dietary fat (Fig. 1). During 
prolonged fasting, glycerol released from lipolysis of triglycerides in adipose tissue 
may account for nearly 20% of gluconeogenesis (Volek JS et al, 2002; Krebs HA, 1964). 
Under conditions when the I/G ratio is low and glucose availability from dietary 
carbohydrate and protein is also very low, it is theoretically possible that lipolysis 
might occur to supply glycerol as gluconeogenic substrate, even when caloric intake 
far exceeds caloric expenditure. 
 
 19 
 
 
(from Westman et al, 2003) 
 
The low carbohydrate intake leads to reduction of serum insulin, which in turn 
downregulated several glycolytic and lipogenetic enzymes (Bortz WM et al, 1972). 
Besides low insulin, it is known that high-fat diets (including KD) upregulate the 
nuclear hormone receptor family peroxisome proliferatoractivated receptors (PPARs), 
particularly types alpha and gamma, which would contribute directly to fatty acid 
(FA) trafficking and oxidation, and indirectly to ketone bodies production (Vazquez 
JA, 1994; Ribeiro L et al, 2008). 
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1.2.4 Regulation of ketogenesis  
 
The KD derives its name from its capacity to cause substantial increases in blood 
ketone bodies (Cullingford TE, 2004). Such ketone bodies are generated from blood 
fatty acids, such as the abundant long-chain fatty acid palmitate, that are catabolized in 
the mitochondria of liver hepatocytes by b-oxidation (Fig. 1).  
Breakdown of such long-chain fatty acids potentially generates high concentrations of 
intracellular acetyl-CoA, a key metabolite that is unable to exit the cell.  
However, this situation is normally circumvented by activation of the ketogenic 
pathway, whereby acetyl-CoA is converted to the ketone bodies acetoacetate and 3-
hydroxybutyrate that can be returned to the blood by diffusion (Fig. 1).  
A variety of hormones, subject to changes in blood concentration in response to the 
quality and quantity of the diet, exert potent actions on hepatic ketogenesis (Fig. 1). 
These include the pancreatic-secreted hormones insulin and glucagon that respectively 
repress and stimulate ketogenesis in response to changes in blood glucose, and the 
adrenal cortex-secreted glucocorticoids that stimulate ketogenesis in response to 
increased stress. 
 
Fig.1 Ketogenesis (from Cullingford TE, 2004) 
 
Thus, under conditions of a freely consumed ‘normal’ high-non-fat/ low-fat diet, 
ketogenesis from fatty acids is at very low levels. This is the result of the relatively high 
blood levels of the ketogenesis-inhibiting hormone insulin, and the elatively low blood 
levels of ketogenesis-promoting hormones glucagon and cortisol. Conversely, 
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underconditions of starvation or the KD, blood insulin levels are low, whereas 
glucagon and cortisol levels are high, thus providing a hormonal milieu that promotes 
hepatic ketogenesis. 
 
As many as 20 enzymes catalyse the steps required to breakdown a fatty acid such as 
palmitate to ketone bodies (Vockley J et al, 2002). Amongst these, certain such enzymes 
appear to have a major regulatory role in the hormonal regulation of ketogenic flux, at 
the level of changes in expression of their corresponding genes (Hsu MH et al, 2001). 
These include long-chain fatty acyl-CoA synthase 1 (ACS1), carnitine palmitoyl 
transferase 1a (CPT1a) and mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase 
(HMGCS2), the critical enzyme of ketogenesis from acetyl-CoA (Cullingford  TE et al, 
1999). 
Blood fatty acids, as well as blood hormones, themselves adopt a hormone-like role by 
regulating expression of genes encoding enzymes of fatty acid oxidation and 
ketogenesis. For example, fatty acid levels in blood will rise during starvation, as fat 
reserves in the body are released into blood. Similarly, fatty acid levels may rise under 
KD-induced conditions of calorie restriction (semi-starvation) and high fat intake.  
In the early 1990s, the hepatic fatty acid ‘hormone’ receptor was identified as the 
peroxisome proliferator-activated receptor a (PPARa) (Issemann I  et al, 1990). As there 
is a far greater range of different fatty acids to glucocorticoids, this would argue in 
favor of a range of receptors similar to PPARa in hepatocytes. Whilst it is true that two 
sister receptors, PPARg and PPARd have been identified, their abundance in liver is 
relatively low compared to PPARa (Escher P et al, 2000). 
Recent evidence suggests that HMGCS2 and PPARa have an especially important 
relationship in promoting ketogenesis during fasting. 
The astrocytes generate ketone bodies from palmitate (Auestad N et al, 1991). At the 
time, such a notion contradicted a central dogma of neurobiology, stating that brain 
consumes but does not produce ketone bodies (Hawkins RA et al, 1971), providing the 
first evidence of a direct molecular effect of the KD on gene expression in brain. In this 
regard, exciting recent findings demonstrate that the KD in children causes increases in 
blood polyunsaturated essential fatty acids (Fraser DD et al, 2003) known to be both 
potent PPARa ligands and to be avidly extracted from blood by the brain, via specific 
receptor uptake systems in the blood–brainbarrier. Ketone bodies produced by liver, 
constitute an important energy source for other organs including brain and muscle. In 
an analogous fashion, it is currently being proposed that astrocyte-derived ketone 
bodies provide fuel for surrounding ketone body-consuming cell-types, such as 
neurons (Guzman  M et al, 2001). This may constitute another of the proposed 
‘metabolic dialogs’ that occur between astrocytes and neurons. 
Switching from a normal diet to the KD has multiple effects on intermediary 
metabolism: the KD induces increases in certain essential fatty acids in the blood and a 
KD administered to humans causes significant decreases in fasting serum triglycerides, 
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postprandial lipemia after a fat-rich meal, together with a tendency to increase HDL 
cholesterol (Sharman MJ et al, 2002). Moreover, the calorie restriction aspect of the KD 
appears responsible for significantly reducing blood glucose levels in mice (Greene AE 
et al , 2001). 
 
Greene AE et al show the importance of blood glucose levels as a predictors in 
susceptibility of epileptogenesis in epileptic mice: the key of this effects could be 
reduction brain energy provided by glycolisis. Reduced glycolytic energy would be 
expected to deplete the reserves of immediately available energy necessary for seizure 
initiation and spread; although ketone bodies provide adequate energy for most brain 
activities under normal conditions, they alone are unable to deliver the immediate and 
large amount of necessary energy for seizure initiation  and maintenance . 
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2 STATE OF ART 
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2.1 Effects of the ketogenic diet on nutritional status 
 
Besides its effects on the central nervous system, the KD may predispose to nutritional 
deficits in energy, proteins, minerals, and vitamins and excess in lipids, saturated fat, 
and cholesterol (Tagliabue A et al, 2012; Park S et al, 2011; Lord K, 2010). For these 
reasons, the use of such an unbalanced diet requires strict adherence to the dietary 
plan and particular attention to implementation and monitoring, particularly at a 
young age (Zupec-Kania B et al, 2008). Importantly, most of the side effects from the 
KD seem to be related to energy and nutrient deficiencies (Rogovik AL et al, 2010). 
  
Only few studies were performed to study the effect of KD on nutritional status.   
 
A 6-month prospective, single-arm observational study was designed to assess he 
metabolic effects of the KD in patients with medically refractory epilepsy treated with 
the KD. The main outcome measures were the change from baseline in nutritional 
status, resting energy expenditure (REE), and substrate oxidation. A total of 18 
Caucasian Italian patients with medically refractory epilepsy (8 males and 10 females, 
mean age: 12.4 _ 5.6 years) were enrolled in this study. 
Initially, patients were admitted to the Child Neuropsychiatry Department and during 
a fasting phase of 12-36 h (only water being allowed), blood sugar, vital parameters 
and urine ketones were checked every 4 h. Once urine ketone levels reached 80-160 
mg/dL, participants were started on the KD on a 4:1 ketogenic ratio.  
The initial calorie prescription was based on an average between this prediet intake 
and recommendations from Johns Hopkins protocol for energy requirements on the 
KD but taking into account weight and height (both current and recent trends), and 
physical activity levels. Alterations in calorie prescriptions were made as needed 
during the course of follow-up. A minimum of 0.8-1 g of protein from animal sources 
(e.g. eggs, milk, meat, poultry and fish) per kilogram of body weight per day was 
given. All participants received sugar-free multivitamin and mineral supplements 
according to the patient’s age and sex. 
Standard anthropometry was carried out by one operator using conventional criteria 
and measuring procedures. The reference standards published by the Centers for 
Disease Control and Prevention (2000) were used to calculate the age- and sex-specific 
z-scores for weight, height and BMI.  
Fat mass (FM) and fat free mass (FFM) were determined by dual energy X-ray 
absorptiometry (DXA) using a Lunar DPX-IQ scanner (Lunar Corp, Madison, WI, 
USA). REE was measured with an open-circuit ventilated-hood system (Sensor Medics 
29, Anaheim, CA, USA). All measurements were performed in the post-absorptive 
state (12-14 h fast) in a thermoneutral environment (ambient temperature 24-26°C) in 
the absence of external stimuli. The respiratory quotient (RQ) was calculated from the 
ratio: RQ ¼ CO2 produced/O2 consumed. 
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The total energy intake did not differ significantly before and after the completion of 
the study. Adherence to the KD protocol was documented by constant ketonuria in all 
subjects. All of the children tolerated the dietwell, and therewere no adverse events. 
The seizure frequency decreased from a median of 5 per day (interquartile range: 1-20) 
at baseline to 2 per day after 6 months of KD (p < 0.001; Wilcoxon signed-rank test). 
The results of this pilot study indicate that administering a KD for 6 months increases 
fat oxidation and decreases the respiratory quotient, without appreciable changes in 
REE.  
Height, weight, and BMI z-scores after 6 months of the KD remained roughly constant 
compared with baseline values. This is important and reassuring, as it clearly suggests 
that a tradition KD can provide an adequate calorie intake to ensure a proper growth 
during childhood and adolescence. These results are in line with those by Vining et al. 
who showed that the KD generally provides sufficient nutrition to maintain growth 
within normal parameters over a defined period. However, it is known that very 
young children may grow poorly on the KD and should be followed-up carefully 
over long periods of use (Rogovik AL et al, 2010).  
These data are also in line with a previous retrospective study (Bertoli S et al., 2002) 
with seven child (1 females and 6 males) aged between 3-16 years performed to assess 
nutritional status during KD evaluating anthropometric measurements (weight, 
height, skinfold and circumferences), bone mineral content and bone mineral density, 
with x-ray energy absorptiometry (DXA) and some biochemical parameters.  Authors 
found any short term modifications (six months) concerning growth, and biochemical 
parameters in child treated with KD. 
A very recent case report (Bertoli et al, 2013) describes the effect of KD on bone health 
after a long period of diet (5 years): any significant modification in term of BMD was 
detected. 
 
Resting energy expenditure represents the largest fraction (50-70%) of an individual’s 
total daily energy expenditure (Levine JA et al, 2005). These data clearly indicate that 
there was no change in resting energy expenditure associated with the KD. 
As expected, fat oxidation increased as an adaptation to the high fat intake typical of 
the KD. The consequence of an isoenergetic exchange of fat for carbohydrate is that the 
results can also be interpreted as being an adaptation to a low carbohydrate intake 
(Schrauwen P et al, 2000). In particular, fat oxidation can be raised on high-fat diets by 
maintaining glycogen concentrations in a lower range. Although the very low 
carbohydrate intake must have resulted in reduction of the glycogen stores, this was 
not, however, detectable in terms of body weight and BMI. It therefore seems that the 
glycogen content of the body decreased until a new concentration was reached in 
which fat oxidation was sufficiently elevated to become in equilibrium with the 
elevated fat intake. It is also possible that fat oxidation was elevated because of 
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increased enzymatic capacity for fat oxidation, which occurred because of the exposure 
to the KD (Schrauwen P et al, 1997). 
Authors found that the increase in fat oxidation was the main independent predictor of 
the reduction in seizure frequency. This preliminary result seems to suggest that 
certain fat oxidation products may be directly or indirectly involved in the reduction of 
seizure frequency induced by the KD. In this regard, an experimental study by Harney 
et al (Harney JP et al, 2002) has shown that acute inhibition of fatty acid oxidation in 
KD-fed animals resulted in a shorter latency to experimentally-induced seizures, 
which was accompanied with a drop in plasma b-hydroxybutyrate levels. 
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2.2 Effect of KD on growth 
 
Literature data shows that growth (height and weight) may be impaired in children 
treated with KD. 
 
Vining et al performed a prospective cohort study of 237 children (130 males, 107 
females) placed on the ketogenic diet for control of intractable epilepsy (mean age at 
starting diet 3 years 8 months; age range 2 months to 9 years 10 months; average length 
of follow-up was 308 days): they found a rapid drop in weight z scores in the first 3 
months. After this initial period, the weight z score remained constant in children who 
started the diet below the median weight for their age and sex, although z scores 
continued to decrease in children starting above the median. There was a small 
decrease in height z scores in the first 6 months (<0.5); however, there were larger 
changes by 2 years. Authors conclude that the KD generally provides sufficient 
nutrition to maintain growth within normal parameters over a defined period; very 
young children grow poorly on the diet and should be followed-up carefully over long 
periods of use. 
 
Liu et al  performed a prospective, nonrandomized study design was used to assess 
the nutritional status of children treated with the classic and medium-chain 
triglyceride (MCT) ketogenic diets. They measure nutrient intakes, growth, and 
biochemical indexes of children, age 1 to 16 years, with intractable epilepsy before and 
after 4 months' treatment with the classic and MCT ketogenic diets an revealed a 
statistically significant height increases of 2 to 3 cm (P<.05), but not a significant 
increases in height/age percentiles. Weight percentiles decreased by approximately 10 
percentiles for both diets; P=.043 for classic diet and.051 for MCT diet.  
 
It is clear that the more longterm the measurement period, the more accurately a 
conclusion can be reached about the impact of ketogenic diet treatment on growth. 
 
Couch et al  found no problems with either weight or height in their group of children 
after 6 months on the diet. 
 
In contrast, Neal et al found a reduction of weight z scores between baseline and 3, 6, 
and 12 months; height z scores showed no change at 3 months but decreased 
significantly by 6 and 12 months. This was more significant in the younger children. 
The increased problems in the younger age group are likely to be attributable to their 
faster growth rate at this age. 
There also seemed to be no correlation between either the energy or protein intake of a 
child and the gradient of their lines of best fit for weight, height, or BMI. 
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As we reported above, none reduction in term of height, weight, and BMI z-scores 
after 6 months of the KD compared with baseline values was found in both clinical 
studies (Tagliabue et al, 2012; Bertoli et al, 2013) investigating nutritional status of 
patients treated with KD in short and long term period. 
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2.3 Effect of KD on lipid metabolism  
 
Lipid abnormalities are a well known side effect of KD.  
 
Whether a very high-fat diet can induce elevated levels of the triglyceride-rich VLDL 
and the cholesterol-rich LDL but lower levels of HDL cholesterol is an important 
question, because each of these effects predicts the development of early 
atherosclerotic lesions, fatty streaks, and fibrous plaques in aorta and coronary arteries 
in adolescents and young adults.  
 
Literature data show that on average, lipid profiles were not significantly affected at 
the most recent follow-up or over time. In fact, Groesbeck D et al found cholesterol, 
triglycerides, and low-density lipoprotein cholesterol were lower, and high-density 
lipoprotein cholesterol was higher, than previously reported by Kwiterovich et al: in 
their study total cholesterol increased by 23mg/dl and triglycerides decreased by 
23mg/dl over at least 6 years, in comparison with an increase of 58mg/dl for both in the 
previous report over only 6 months. 
 
Both studies revealed that the trend showed a gradual return towards baseline values 
over 2 years and that after 2 years this trend seems to continue. 
 
The authors conclude that the alteration of lipid profile may not have short term 
effects, but the long term relevance of this finding is unknown over the lifetime of a 
patient. 
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2.4 KD and visceral fat 
 
The metabolic side effects of KD that contribute to the diet discontinuation in children 
include hypoglycemia, hyperlipemia, weight loss, and inadequate growth (Hartman et 
al, 2007). 
 
These metabolic alterations, together with the increased hepatic gluconeogenesis drive 
some authors to investigate the alteration of adipose glyceroneogenesis also would be 
altered in rats fed with KD and this alteration. 
 
Literature data show a decreased weight gain in rats fed with KD during the first 6 wk  
(Ziegler et al, 2002). 
 
In contrast to this decreased body weight gain, it has been observed (Ribeiro L et al, 
2008) an increment in white adipose tissue (epididymal plus perirenal fat mass 
weight); white adipose tissue (WAT) weight to body weight ratio in KD-fed rats was 
2.4 x higher and constant during all 6 week.   
 
In order to investigate WAT accumulation in rats, Ribeiro et al measured PEPCK , the 
rate-limiting enzyme for glyceroneogenesis. Ketogenic diet-fed rats have increased fat 
mass and PEPCK activity. Interestingly, liver PEPCK was lower in KD-fed rats but 
they found elevated activity of this enzyme in adipose tissue of KD-fed rats. This high 
activity provides enough Gly-3P for the synthesis of TAG in adipose tissue, smoothing 
the putative elevated lipidemia during KD feeding. Confirming the “TAG saving 
activity” of the visceral adipose tissue, circulating lipids in KD-fed rats were normal, in 
agreement with other studies in human and rodents.  
Whether high fat intake is accompanied by normal lipidemia it may be possible that a 
very efficient system for lipid storage and/or expenditure is taking place.  
 
Ribeiro et al observed a clear change in the glucose tolerance in animals fed with KD, 
possibly resulting from insulin resistance. The visceral lipogenesis was supported by 
an increment in adipocyte PEPCK, aiming to provide glycerol 3-phosphate to 
triacylglycerol synthesis and this fat accumulation was accompanied by glucose 
intolerance.  
These data contribute to understanding of the metabolic effects of the KD in adipose 
tissue and liver and suggest some potential risks of this diet, particularly visceral fat 
accumulation. 
 
Despite the fact that weight loss and inadequate growth have been described in 
children under KD (Peterson et al, 2005, Hartman et al, 2007,  Vining et al, 2002, Liu et 
al 2003), fat accumulation (visceral or other) has not been reported in these children.  
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In fact, poor weight gain is observed in young humans and rodents under KD, 
controlling caloric intake or ad libitum administration, but the metabolic long-term 
reasons for this finding are still unclear (Peterson et al, 2005;  Ziegler et al, 2002; 
Likhodii SS et al, 2002; Kennedy et al, 2007). 
 
The visceral lipogenesis was accompanied by glucose intolerance. This apparent 
insulin resistance also has been reported in KD-fed rats subjected to insulin-induced 
hypoglycemia (Yamada KA et al, 2005). On the other hand, an increase in insulin 
sensitivity has been described in children during KD (Johnston CS et al, 2006). It is 
important to mention that KD is not prescribed ad libitum to children refractory to 
conventional anti-epileptic drug treatment. Caloric restriction per se appears to induce 
an increment of hepatic PEPCK activity (Spindler SR, 2001). Possibly KD with caloric 
restriction also increases adipose PEPCK activity. 
However, this issue also deserves further investigation.  
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2.5 KD and glucose tolerance 
 
Some authors tried to investigate the glucose tolerance and insulin sensitivity during 
KD but it remains unclear in either human or animal studies whether low 
carbohydrate-high fat (LC-HF) diets are beneficial for glucose and insulin metabolism . 
 
Badman et al. reported that circulating glucose and insulin concentrations were 
reduced and insulin sensitivity improved in obese mice fed a ketogenic (LC-HF diet), 
with no adverse effects on glucose metabolism in lean, wild-type mice fed the same 
diet.  
However, Jornayvaz et al. reported opposing findings, with hyperinsulinemic 
euglycemic clamps showing that ad libitum consumption of a ketogenic LC-HF diet 
induces hepatic insulin resistance in lean mice despite diet-induced reduction of body 
weight.   
Other authors have reported weight loss and improved glucose tolerance during 
IPGTTs and ITTs in obese but not in lean wild-type mice fed a ketogenic LC-HF diet 
(Kennedy AR et al, 2007). 
 
In a third study, Garbow et al. reported development of glucose intolerance with no 
effect on systemic insulin sensitivity in lean C57BL/6 mice fed a ketogenic LC-HF diet 
for 12 wk. These authors suggested that the preserved response to insulin was 
explained by their lower lean mass resulting in a proportionally higher insulin 
dose in insulin tolerance tests compared with controls 
 
 
In a very recent study Bielohuby et al (2013) found that two important aspects have not 
been studied. 
First, it is not clear whether LC-HF diets per se affect glucose tolerance or whether the 
relative abundance of protein and fat in the diets plays a role. Second, the role of 
energy intake with LC-HF diets has not been studied until today.  
Previous data showed that the isoenergetic pair-feeding setting of the LC-HF diets 
results in visceral fat accumulation (Bielohuby M et al, 2011; Bielohuby M et al, 2011; 
Caton SJ et al, 2012). To exclude that the factor fat accumulation exerts significant 
effects on glucose and insulin metabolism, they also investigated LC-HF diets in a 
hypocaloric setting, where we restricted the access of the rats to only 80% of the 
regular pair-fed groups, which prevented fat accumulation and resulted in a 
comparable fat mass between LC-HF groups and rats fed the control diet. 
They show that rats fed LC-HF diets exhibit impaired glucose tolerance and insulin 
resistance despite showing reduced glucose and insulin levels. Glucose intolerance 
was observed with both LC-HF diets. The use of isoenergetic pair-feeding ensured that 
the effects were not due to energy overconsumption. In addition, caloric restriction of 
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LC-HF to 80% of the isoenergetic pair-fed groups revealed that the glucose-intolerant 
phenotype is not dependent upon visceral fat accumulation. 
In this study, reduced glucose tolerance was observed alongside insulin resistance 
despite reduced circulating concentrations of glucose and insulin in animals fed LC-HF 
diets.  
 
In this investigation, as well as in previous studies (Bielohuby M et al, 2011; Bielohuby 
M et al, 2011; Caton SJ et al, 2012), isoenergetic feeding of the Atkinsstyle and the 
ketogenic LC-HF diet resulted in a significant accumulation of visceral fat mass in rats 
compared with chow controls. No significant differences in the degree of visceral fat 
accumulation between the two LC-HF diets were detected, which is in accord with 
previous studies in which unchanged circulating leptin between LC-HF-1 and LC-HF-2 
was also shown (Bielohuby M et al, 2011).  
 
Results from literature suggest that insulin resistance occurs at two sites. 
First, hepatic insulin resistance was observed most likely because of diet-induced 
hepatic fat accumulation (Bielohuby M et al, 2011; Jornayvaz et al, 2010), the 
nonalcoholic fatty liver disease-like phenotype (Garbow et al, 2011), and associated 
impairment of hepatic insulin signaling (Jornayvaz FR et al, 2010).  
In addition, hyperinsulinemic euglycemic clamp and insulin tolerance test (ITT)  
experiments provided evidence for peripheral insulin resistance. This could be due to 
lower lean body mass of rats fed LC-HF diets. However, Bielohuby et al also observed 
greater accumulation of intramyocellular lipids and higher triglyceride concentrations 
in gastrocnemius muscle samples from rats fed both LC-HF diets, which have been 
shown to be an early marker for the development of insulin resistance (Bredella MA et 
al, 2009). 
 
A study (Rauchenzauner M et al, 2008) with children affected by Glut1 deficiency 
indicate a characteristic effect of a long-term ketogenic diet on glucose and lipid 
homeostasis. Patients with Glut1 deficiency usually require the KD for years. It has 
been stated that the KD does not reduce glucose signaling, thus possibly preventing 
and/or reversing obesity (Mobbs CV et al, 2007). In this study, significantly lower 
serum insulin concentrations and HOMA-IR in patients confirmed this notion, 
reflecting the reduced carbohydrate intake on a KD. Of note, similar fasting glucose 
concentrations in both groups do not support the perception of hypoglycemic risk 
during long-term KD.  
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2.6 The overflow hypothesis 
 
A consensus has emerged that central fat is particularly damaging because of  the well-
known link with greater risk for diabetes, cardiovascular disease, hypertension, and 
certain cancers. 
It is also accepted that insulin resistance is a related characteristic that may be an 
essential link between central fat and disease risk and many authors have suggested 
that one or more moieties secreted by the visceral adipocyte might mediate insulin 
resistance. Particularly, there are free fatty acids (FFAs)1 themselves (“portal theory”) 
or the adipose tissue–released cytokines (adipokines) such as interleukin-1, 
interleukin-6, tumor necrosis factor-alpha, resistin, or a reduction in adiponectin, 
which has been repeatedly shown to be associated with reduced insulin resistance. 
 
Bergman et al (Bergman R et al, 2006) postulates that the visceral fat is involved in this 
mechanism because FFAs per se are among the most important products of the visceral 
adipocyte to cause insulin resistance (and hence the metabolic syndrome) and because  
the anatomical position of the visceral adipose depot (i.e., portal drainage into the 
liver) plays an important role in the pathogenesis of the metabolic syndrome. 
 
To investigate these items, they developed the obese dog model. One similarity 
between dogs and humans is the wide variance in fat deposition in a “wild” or 
“natural” population.  
Interestingly, there is a tendency for visceral adiposity to increase rapidly as one 
examines animals with increasing body fat; the visceral fat depot tends to plateau, and 
subcutaneous fat increases more rapidly with overall obesity. This tendency for 
visceral fat to increase and plateau may be responsible for the sharp reduction in 
insulin sensitivity in leaner individuals, with insulin resistance being similar in human 
subjects with BMI levels >30 kg/m2 (Garcia-Estevez DA et al, 2004). 
Regardless of basal adiposity, increasing the content of fat in the diet induces visceral 
as well as subcutaneous fat in the dog model.  
In fact, an isocaloric diet with increased fat from 35% to 43% had a potent effect on 
insulin sensitivity— but the effect was almost totally on liver sensitivity to 
insulin (Kim SP et al, 2003).  On the contrary, peripheral tissues remained surprisingly 
sensitive to hyperinsulinemia. The authors conclude that increased visceral adiposity 
induced by fat feeding causes a primary insulin resistance of the liver.  
 
Increasing fat in the diet to achieve an hypercaloric intake induced both hepatic and 
peripheral insulin resistance: the authors proposed the “overflow hypothesis”: 
extremely lean individuals are insulin sensitive at the liver and in muscle tissue; 
increasing fat in the diet is proposed to store visceral and subcutaneous fat, but the 
liver is exquisitely sensitive to fat in the visceral depot, leading to hepatic insulin 
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resistance primarily (i.e., effect of physiological insulin to suppress glucose output) 
that is observed with moderate visceral adiposity; further fat intake results in systemic 
(i.e., muscle) insulin resistance associated with fat deposition in the subcutaneous 
tissues.  
The expression of enzymes related to lipid turnover in visceral fat (e.g., lipoprotein 
lipase, hormone sensitive lipase, peroxisome proliferator-activated receptor γ) increase 
with fat feeding in visceral fat relative to subcutaneous fat and this can enhance flux of 
FFAs through the portal vein to the liver, as well as to other tissues.  
However, Bergman didn’t found evidence that expression of “adipokines” was 
increased specifically in visceral fat tissues (tumor necrosis factor alpha, interleukin-6, 
adiponectin, leptin), to support the concept that FFAs themselves are responsible for 
the insulin resistance of the liver, at least with moderate increases in fat intake.  
Of course, their results may not extrapolate to the human obese model, which usually 
represents years of overweight in which adipokines could contribute substantially to 
insulin resistance. 
 
The explanation for the relationship between visceral fat deposition, in particular, and 
components of the metabolic syndrome, including insulin resistance, remains obscure; 
on the other hand the possible effect of FFAs in the role of inducing liver insulin 
resistance, which is the primary event in the development of the metabolic syndrome 
in animal models (Kraegen EW et al, 1991; Yun-Jung Bae et al, 2013) is not well 
determinate.  
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2.7 Adipocytokines and metabolic syndrome 
 
Metabolic Syndrome is associated with obesity and with metabolic stresses as a 
consequence of adipose cell enlargement and the associated changes in circulating 
inflammatory cytokine and adipokines (Yun-Jung Bae et al, 2013). Obesity-related 
chronic or lowgrade systemic inflammation is considered to be a common in both 
insulin resistance and atherogenesis which promotes the development of type 2 
diabetes and atherosclerosis.  
 
Adipokines are cytokines mainly produced by the adipose tissue.  
Leptin, adiponectin, resistin and visfatin are known to contribute to inflammatory 
responses.  
Adiponectin inhibits the nuclear factor-ĸB (NF-ĸB)-dependent synthesis of 
tumornecrosis factor (TNF) and interferon-γ (IFNγ), and induces the production of 
interleukin-10 (IL-10) and IL-1 receptor antagonist (IL-1RA) (Wolf AM et al, 2004).  
Leptin signals to induce activation of the mitogen-activated protein kinases (MAPKs) 
p38 and extracellular- signal-regulated kinase (ERK), and induces the production of 
nitric-oxide synthase 2 (NOS2) and reactive oxygen species (ROS).  
Adiponectin induces apoptosis of monocytes and inhibits phagocytosis by 
macrophages, whereas leptin enhances macrophage phagocytosis and induces the 
activation, proliferation and migration of monocytes .  
 
Biomarkers of systemic inflammation other than adipokines include pro-inflammatory 
cytokines and chemokines which have been suggested to be closely related to excess 
adipose tissue accumulation. TNF-α which can initiate both acute and chronic 
inflammation increases production of IL-6 and monocyte chemoattractant protein 1 
(MCP1), and facilitates endothelial dysfunction. MCP1, a mediator for T lymphocyte 
recruitment and monocyte trafficking, is increased by leptin, obesity, and insulin-
resistance-inducing hormones. 
Also, cellular adhesion molecules (CAMs) mediate adhesion of circulating leukocytes 
to endothelial cells, promoting subsequent transendothelial migration.  
 
More recently, visceral fat as a metabolically active tissue has been suggested to have a 
close relationship with metabolic syndrome. It is associated with higher production of 
inflammation mediators including TNF-α , plasminogen activator inhibitor-1 (PAI-1), 
IL-6, and hsCRP . Previous studies have also suggested that the presence of metabolic 
syndrome was associated with higher levels of IL-6, TNF-α, and hsCRP and with lower 
levels of adiponectin. 
 
Devaraj and colleagues reported that low adiponectin was the strongest predictor of 
metabolic syndrome (OR, 2.5; 95% CI, 1.3-4.5).  
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Adiponectin is the most abundant adipokine in circulation and it exerts anti-
inflammatory activity. It has been demonstrated that adiponectin modulates insulin 
sensitivity by stimulating glucose utilization and fatty acid oxidation via 
phosphorylation and activation of AMPK in muscle and liver. Adiponectin also 
possesses vasculo-protective effects which are mediated by promoting vasodilatation 
and vascular repair, and inhibiting ROS formation, macrophage activation and smooth 
muscle cell proliferation.  
 
Among others, ICAM, hsCRP and TNF-α concentrations exhibited strong correlations 
with the metabolic syndrome;  hsCRP is a marker of systemic inflammation which has 
been known to be related to cardiovascular disease risk factors such as obesity, high 
blood pressure, apolipoprotein B and fibrinogen. hsCRP is also known to impair 
insulin signaling. In previous studies, strong associations between hsCRP and insulin 
resistance have been reported.  
TNF-α is a most representative pro-inflammatory cytokine which is produced mainly 
by macrophages and lymphocytes; IL-6 is another pro-inflammatory cytokine related 
to insulin resistance. IL-6 has also been shown to facilitate the hepatic production of 
hsCRP .  
 
Leptin is known as a TNF-α inducer while adiponectin is a suppressor.  
It has been stated (Chen S-J et al, 2012) that a higher level of hs-CRP (high sensitivity 
C-reactive protein)  (≥1.00 mg/L), or IL-6 (≥1.50 pg/mL) or a lower level of adiponectin 
(<7.90 µg/mL) were associated with a significantly greater risk of metabolic syndrome 
(MS). Subjects suffering from MS may have a higher inflammation status and a higher 
level of oxidative stress. A higher inflammation status was significantly correlated with 
decreases in the levels of antioxidant enzymes and adiponectin and an increase in the 
risk of MS.  
 
Yun-Jung Bae et al performed also abdominal subcutaneous adipose tissue (SAT) and 
visceral adipose tissue (VAT) measures by CT to determine the relationship between 
fat tissue mass and biomarkers. Adipose tissue pathogenicity differs according to 
adipose tissue localization. VAT was suggested as an independent predictor of 
impaired glucose tolerance, elevated blood pressure, and dyslipidemia. It is more 
susceptible to lipolysis than SAT and is associated with a higher production of hsCRP.  
Literature data showed that SAT and VAT were similarly associated with elevated 
concentrations of multiple inflammatory biomarkers; in this study results indicated 
that both VAT and SAT were significantly related to leptin and hsCRP. This finding 
indicated that both VAT and SAT contributed to the elevated production of 
inflammation-related molecules. 
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No data are available on VAT assessment and relationship with glucose intolerance, 
insulin resistance and markers of metabolic syndrome in human treated with KD. 
 
In a study listed below (Rauchenzauner M et al, 2008)  the authors investigate glucose 
metabolism, lipid profile, and adipocytokines: leptin, soluble leptin receptor (sOB-R), 
adiponectin in prepubertal children with Glut1DS after a long term treatment with KD. 
They found a proatherogenic lipoprotein profile, showing Greater ApoA-I and ApoB 
concentrations as well as lower LDL-C/ApoB and HDL-C/ApoA-I ratios in children 
treated with the KD. The increase in ApoB-containing particles might be the result of 
an enhanced exchange of triglycerides in VLDL for cholesterol-rich lipoproteins by 
cholesteryl ester transfer protein (CETP), accompanied by hydrolysis of triglycerides in 
LDL-C by hepatic lipase and lipoprotein lipase (Kwiterovich et al, 2003).  
Alternatively, a direct influence of the KD on lipolytic enzymes might impede the 
formation of small, dense LDL-C. Therefore, measurement of ApoA-I and ApoB 
provides additional information on absolute numbers and particle size of HDL-C and 
LDL-C, known to be associated with cardiovascular risk profile (Sandhofer A et al, 
2003). 
Adipocytokines are considered a potential link between glucose and fat metabolism 
(Tilg H et al, 2006; Dashti HM et al, 2007). Interestingly, the results of the present study 
point toward low body fat mass due to low leptin and high sOB-R concentrations. Of 
importance, this is consistent with findings in adults with rheumatoid arthritis or 
diabetes mellitus treated with a KD (Fraser DA et al, 2000; Thio LL et al, 2006). 
Nevertheless, low levels of leptin are in contrast to increased leptin concentrations 
recently observed in young rats on a KD (Thio LL et al, 2006). Therefore, the potential 
mechanism of increased leptin levels contributing to the anticonvulsant effect of a KD 
appears to be unlikely in children with Glut1DS.  
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2.8 Neuronal network and adipocytokines 
 
A complex neuronal network involving multiple peripheral and central hormones 
regulates appetite and body weight: the network helps the body to meet its 
homeostatic needs, but it also makes eating a pleasurable or hedonic activity. 
Anatomically, hypothalamus and nucleus accumbens have a critical role in the 
network, which also depends on several cortical areas including the orbitofrontal area, 
dorsal prefrontal area, hippocampus, and motor cortex. The network involves other 
subcortical structures such as the thalamus and striatum and brainstem nuclei such as 
the locus coeruleus. Obviously, the areas of the brain involved in regulating 
macronutrient, micronutrient, and energy homeostasis must receive information 
regarding the body’s nutritional status from the other organs of the body.  
Neurohormones released from these organs provide the brain with this information. 
Vagal afferents and the hypothalamus play a key role in this process. 
The arcuate nucleus is constituted by two different sets of neurons: AgRP / NPY and 
Pomc / Cart. Among them there is a relationship of mutual inhibition. Afferent signals 
can be classified into satiety signals and signals of appetite (ghrelin) and satiety 
(insulin and leptin). 
 
The brain responds to changes in insulin, leptin, and ghrelin because neuropeptide Y 
(NPY)/Agouti-related protein (AgRP) and proopiomelanocortin (POMC)/cocaine- and 
amphetamine-regulated transcript (CART) neurons in the arcuate nucleus have 
receptors for these neurohormones.  
Insulin and leptin stimulate POMC/CART neurons and inhibit NPY/AgRP neurons 
whereas ghrelin stimulates NPY/AgRP neurons. 
Activation of POMC/CART neurons has an anorexigenic effect while activation of 
NPY/AgRP neurons has an orexigenic effect. When stimulated, POMC/CART neurons 
suppress food intake by releasing alpha-melanocyte stimulating hormone at synapses 
on higher order neurons in the network. 
In an analogous manner, activation of NPY/AgRP neurons causes the release of NPY 
and AgRP, which ultimately increase food intake by modulating higher order neurons 
in the network. 
 
While on a ketogenic diet, the body obtains most of its calories from fat rather than 
carbohydrates and this dramatic change in caloric composition results in a unique 
metabolic state, and some of the expected metabolic changes in serum include 
increased ketones and an altered lipid profile (Liu Lin Thio, 2012). Though studies 
typically report increases in ketones ranging from 2 to 10 fold, not all studies report in 
human increased total cholesterol, low-density lipoprotein cholesterol, and 
triglycerides. 
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In rodents, the ketogenic diet can double fat mass as a percentage of total body mass.  
An expected consequence of the increase in fat mass is an increase in leptin because 
leptin levels are proportional to fat mass (Maffei et al., 1995). Several studies confirm 
this prediction by showing that the ketogenic diet may more than double serum leptin 
levels though some find no change (Kennedy et al., 2007). 
The ketogenic diet generally decreases serum glucose by 10—30% in humans and 
rodents. This reduction in serum glucose may produce or reflect a change in insulin. 
Accordingly, several studies in rodents demonstrate that ketogenic diets lower serum 
insulin by at least 25%.  The decrease in insulin is a more consistent finding than the 
increase in serum leptin levels. 
The ketogenic diet also affects other peripherally released hormones including ghrelin 
and cortisol. Serum ghrelin levels increase or do not change in rats. In humans and 
rats, serum cortisol levels increase by 20% or more. The finding that the ketogenic diet 
concurrently can increase leptin and decrease insulin is unique because generally 
metabolic changes cause leptin and insulin levels to change in concert with both either 
increasing or decreasing.  
The ketogenic diet does not alter NPY gene expression in the hypothalamus and other 
brain regions (Kennedy et al., 2007; Kinzig and Taylor, 2009). It also does not modify 
AgRP gene expression in the hypothalamus (Kennedy et al., 2007).  Surprisingly, the 
diet decreases POMC expression in the hypothalamus even though leptin should 
increase its expression (Kennedy et al., 2007; Kinzig and Taylor, 2009; Kinzig et al., 
2010). 
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(from Liu Lin Thio, “Hypothalamic hormones and metabolism” Epilepsy Research (2012) 100, 
245—251) 
 
Thio et al (Epilepsy research, 2012) postulates that the increase in serum leptin should 
contribute to the ketogenic diet’s anticonvulsant effect because leptin has 
anticonvulsant properties in several in vitro and in vivo models. Like leptin, insulin 
can regulate neuronal excitability by modulating multiple ion channels. (Table 1). 
 
 
(from Liu Lin Thio, “Hypothalamic hormones and metabolism” Epilepsy Research (2012) 100, 
245—251) 
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The increase in serum leptin should  also contribute to the ketogenic diet’s 
neuroprotective effects. Human clinical studies together with in vivo and in vitro 
animal experiments support the hypothesis that the diet may be of benefit in 
neurodegenerative conditions such as Alzheimer and Parkinson disease (Gasior et al., 
2006). It may also protect neurons from damage induced by a variety of insults 
including seizures, ischemia, trauma, and hypoglycemia. Similarly, leptin reduces 
neuronal damage in experimental models of Parkinson disease, ischemia and seizures 
(Signore et al., 2008). 
 
The authors conclude that anticonvulsant and neuroprotective effects of the ketogenic 
diet that involve leptin and insulin probably involve the cell signaling pathways they 
modulate (see Fig. 1).   
Besides modulating ion channels, the cell signaling pathways regulated by leptin and 
insulin have a critical role in controlling cellular growth, proliferation, metabolism, 
and survival as expected from their role in energy homeostasis. The decrease in mTOR 
activity may account for some of the diet’s other beneficial effects besides being an 
anticonvulsant (Fig. 1). Decreased mTOR activity in the brain is consistent with the diet 
also being antiepileptogenic. 
 
These findings are in contrast with those showed in the unique study performed in 
humans and listed below (Rauchenzauner M et al, 2008). In fact, the authors found low 
levels of leptin in GLUT1 patients, that are in contrast to increased leptin 
concentrations recently observed in young rats on a KD. Therefore, the potential 
mechanism of increased leptin levels contributing to the anticonvulsant effect of a KD 
appears to be unlikely in children with Glut1DS.  
Further study are necessary to better clarify this item. 
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2.9 Ghrelin as anticonvulsant 
 
Neuropeptides appear to be of importance when the central nervous system (CNS) is 
challenged, such as during high-frequency firing and pathologic conditions.  
 
Different neuropeptides such as neuropeptide Y, brain-derived neurotrophic factor 
(BDNF), somatostatin, ghrelin, and galanin, act as regulators of diverse synaptic 
functions and along with the classic neurotransmitters. Abnormalities in the regulation 
of synaptic transmission play a critical role in the pathogenesis of numerous brain 
diseases, including epilepsy (Casillas-Espinosa et al, 2012). 
 
Potential advantages of treatments that target neuropeptide systems in comparison to 
classical neurotransmitter systems and ion channels revolve around the subject of 
efficacy as well as safety. Because the occurrence of side effects is dependent on both 
selectivity and potency of a ligand for its receptor, it is expected that targeting 
neuropeptide receptors might result in less pronounced side effects when compared to 
classical neurotransmitters. Indeed, neuropeptides have more discrete neuroanatomic 
localization when compared to classic neurotransmitters (Portelli et al, 2012). They 
have as well an even higher binding affinity for their receptors than neurotransmitters, 
being consequently more potent. It make them attractive candidates for the 
development of new clinical applications for various disorders. The number of 
neuropeptides linked to epilepsy is on the rise, reflecting the increased interest of 
researchers in this domain.  
 
Ghrelin has only very recently been introduced into the field of epilepsy (Portelli et al, 
2012). 
Ghrelin is mainly produced by the X/A-like cells of the oxyntic stomach mucosa and 
centrally by the neurons in the hypothalamus.  
Published rodent studies are simple to interpret, since the majority state that ghrelin 
has anticonvulsant properties. Since in hypothalamic slice preparations it was found 
that ghrelin leads to increased activity of NPY/AgRP (agoutirelated protein) neurons as 
well as an increased rate of c-aminobutyric acid (GABA) secretion (Cowley et al., 2003), 
the group of Obay proposed this stimulatory effect of ghrelin as a possible mechanism 
of action of ghrelin’s anticonvulsant effects (Obay et al., 2007).  
 
Various hypotheses have been put forward in order to identify why KD is so effective 
in treatment of epilepsy. 
Biagini et al show that pretreatment with GHS-R1a agonists results in beneficial effects 
in pilocarpine-treated rats exposed to status epilectus. The neuroprotection afforded by 
ghrelin was completely independent of anticonvulsant effects during prolonged 
seizure exposure. 
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A recent review discussed the possibilities of the involvement of the norepinephrine 
system and the potential contribution of galanin and NPY (Weinshenker, 2008). Apart 
from their anticonvulsant properties, both galanin and NPY are orexigenic 
neuropeptides just like ghrelin.  
 
Experiments in rodents showed that the ketogenic diet did not alter galanin and NPY 
mRNA expression (Tabb et al., 2004) or plasma ghrelin levels (Honors et al., 2009). 
Weinshenker reflects that the absence of neuropeptide changes does not necessarily 
rule out a contribution of orexigenic neuropeptides to the anticonvulsant effect of the 
KD. One possibility could be that the effect of KD on these neuropeptides becomes 
evident following seizure activity. This is where ghrelin differs from galanin and NPY 
because, although ghrelin levels appear to decrease following seizure activity, the 
opposite takes place for NPY and galanin. Therefore, it is of interest that these 
orexigenic neuropeptides are further investigated to elucidate whether or not there is 
indeed a link between their anticonvulsant potential and the ketogenic diet.  
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3 AIMS OF THE STUDY 
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3.1 Aim #1. Nutritional evaluation 
 
To assess the nutritional status of children on KD and to study the effect on: 
- growth  
- resting energy expenditure 
- subcutaneous and visceral adipose tissue 
- lipid and glucose metabolism 
 
To clarify these three aims we enrolled patients on KD and we study the long term 
effects (at baseline and after 12 months).  
 
3.2 Aim #2. Adipocytokines and markers of inflammation 
 
To understand the neurohormonal effects of KD and the neuronal network involved in 
regulating energy homeostasis and to clarify the role of KD on the inflammation 
patterns, well related with metabolic syndrome. 
 
To clarify this aim we enrolled patients starting KD and we study the short term effects 
(at baseline and after 12 weeks).  
 47 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 PATIENTS AND METHODS 
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4.1 Patients and methods of Aim #1 
 
We enrolled 18 patients (6 males/12 females, mean age 11,3 years, range 3,5-23,9) 
treated with KD to study the nutritional status with anthropometric measurements, 
skinfold thickness measurements, Body composition, REE, blood metabolic 
parameters. 
 
All patient are on KD on a 4:1 ketogenic ratio; the diet is calculated on a basis of basal 
metabolism (MB) and daily energy expenditure.  
 
Anthropometric characteristics at baseline: among males only 1/6 was obese; 5/6 
normal weight; among females: 3/12 were underweight, 8 had normal weight; 1/12 was 
overweight. 
 
Anthropometric measurements were taken by the same operator: Body Weight (BW, 
Kg) and Body Height (BH, cm) were measured to the nearest 100 g and 0.5 cm 
respectively. Body Mass Index (BMI) was calculated using the formula: BMI (Kg/m2) = 
BW (Kg)/BH2 (m2).  
 
Skinfold thickness measurements were used to provide an estimate of total body fat 
and were measured as proposed by Lohman et al by means of to Holtain LTD caliper. 
All the measurements were performed on the non-dominant side of the body.  
 
Body composition assessment was performed with a Lunar DPX-IQ scanner (Lunar 
Corp, Madison, WI) equipped with a paediatric software (version 4.6 b). Total body 
scans were performed with subjects in the supine position.  
 
Ultrasound assessment was made with measurements of abdominal subcutaneous 
skin-hepatic thickness (Hepatic AT), abdominal subcutaneous skin-muscle thickness 
(umbilical AT), intra-abdominal muscle-aorta thickness (Aortic AT) (Armellini et al, 
1991). 
 
Plasma glucose and insulin as well as serum lipids and renal and liver tests were 
determined with standard methods. 
 
Resting energy expenditure (REE) was estimated by indirect calorimeter using an 
open-circuit ventilated-hood system (Sensor Medics 29, Anaheim, CA). All 
measurements were made in post-absorptive state (12–14 h fast) in a thermoneutral 
environment (24–26°C) and with no external stimulation.) The calorimeter was 
calibrated at the beginning of each test using two reference gas mixtures (26% O2 and 
74% N2; 16% O2, 4.09% CO2 and 79.91% N2, respectively). 
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Data were collected for 30 min. A 10-min run-in time was allowed for stabilization and 
for participants to acclimatize to the canopy and instrument noise.  
The respiratory quotient (RQ) was calculated from the ratio: RQ = CO2 produced/O2 
consumed.  
The oxidation of carbohydrate and fat was determined from the measurements of O2 
consumption, CO2 production according to the following equations: Carbohydrates 
(mg/min) = 4.585 V CO2 - 3.2255 V O2; Fat (mg/min) = -1.7012 V CO2 + 1.6946 V O2.  
 
All calculations were performed using SPSS version 20.0 for Windows (SPSS, Inc., 
Chicago, IL, USA). A value of p < 0.05 (two-sided) was considered statistically 
significant. 
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4.2 Patients and methods of Aim#2 
 
We enrolled 14 patients (5 males/9 females, mean age 10,02 years, range 1,9-36,8) 
treated with KD to study plasmatic levels of adipocytokines and markers of 
inflammation  
 
All patient are on KD on a 4:1 ketogenic ratio; the diet is calculated on a basis of basal 
metabolism (MB) and daily energy expenditure.  
 
Anthropometric characteristics at baseline: among males only 1/5 was obese; 1/5 was 
underweight; 3/5 normal weight; among females: 4/9 were underweight, 5 had normal 
weight; none was overweight. 
 
Laboratory analyses of all measurements and all patients were done together in the 
metabolic laboratory at the International Center for the Assessment of Nutritional 
Status, University of Milan.  
Serum leptin and serum adiponectin was measured by using an enzyme immunoassay 
kit ( R & D Systems; Wiesbaden, Germany). 
Serum ghrelin was measured by enzyme immunometric assay (BioVendor; Brno, 
Czech Republic).  
Serum IL 6 was measured by a electrochemiluminescence  immunoassay (Cobas, 
Roche diagnostics, Mannheim). 
FFA were measured by a fluorometric assay;  hsCRP and  TNFα with a ELISA test. 
 
All calculations were performed using SPSS version 20.0 for Windows (SPSS, Inc., 
Chicago, IL, USA). A value of p < 0.05 (two-sided) was considered statistically 
significant. 
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5 RESULTS 
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5.1 Results of Aim#1  
 
Characteristics of our sample of patients (sex, age at baseline, neurological disease, 
pharmacological treatment and KD plan) are summarized in Table 1. 
Table 1. Characteristics of the sample of patients. 
  Sex Neurological disease Age (years) 
R.F Male Lafora disease 20,9 
R.E. Female Drug-resistant epilepsy 4,6 
C.F. Male  Lissencephaly and abnormal neuronal migration 8,7 
C.V. Female Drug resistant epilepsy 5,1 
L.S. Female Drug-resistant epilepsy 12,7 
G.D. Male  Drug-resistant epilepsy 11,28 
C.G. Female GLUT-1 deficiency 19,7 
D.P.P. Female GLUT-1 deficiency 21,4 
R.D. Female GLUT-1 deficiency 23,9 
D.S.M. Female Drug-resistant epilepsy 9,1 
P.V. Female Drug-resistant epilepsy 3,54 
C.F. Female Drug-resistant epilepsy 3,9 
C.A. Male  GLUT-1 deficiency 12,2 
B.E. Female Drug-resistant epilepsy 10,3 
G.N. Male  GLUT-1 deficiency 7,8 
B.R.W. Female GLUT-1 deficiency 6,7 
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M.A. Male  GLUT-1 deficiency 10,7 
P.C. Female GLUT-1 deficiency 9,9 
 
 
None statistical difference were found regarding body weight, height and BMI in our 
patients after 12 months of KD; neither waist circumference nor ratio waist 
circumference/height were different before and after KD (Table 2). 
We found any long term modifications concerning skinfold thickness measurements 
(bicipital, triceps, subscapular and sovrailiac thickness and %BF). 
We didn’t found any change of body composition on KD, in term of fat mass (FM, Kg), 
fat free mass (FFM, Kg), bone mineral content (BMC, g), and of ratios between legs, 
harm, trunk and whole body (Table 2).  
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Table 2. Anthropometric and DXA measurements. All data are expressed as means ± 
SD. BMI, body mass index;  
  Preintervention Postintervention %Cha
nge 
P 
value 
 Mean SD Mean SD    
Nutritional status parameters            
Body weight, kg 34,71 20,18 35,92 17,43 3,47 0,248 
BMI, kg/m2 17,68 4,96 17,48 3,57 -1,13 0,647 
BMI z-score -0.44 1,83 -0.32 1,35 -27,27 0,722 
Waist, cm 61,32 14,17 62,55 11,51 1,92 0,161 
Waist z-score 0,71 1,81 0,64 1,24 -9,85 0,839 
Waist/height 0,46 0,06 0,45 0,05 -2,17 0,354 
Bicipital skinfold, mm 7,78 4,15 6,98 3,32 -10,28 0,141 
Tricipital skinfold, mm 11,89 6,63 12,65 5,82 6,39 0,268 
Subscapular skinfold, mm 11,71 9,70 11,88 8,40 1,45 0,803 
Suprailiac skinfold, mm 14,19 11,91 15,72 10,01 10,78 0,129 
% Body fat 21,92 8,47 21,71 7,88 -0,96 0,831 
Waist/height 0,46 0,06 0,45 0,05 -2,17 0,354 
DXA parameters       
FM (g) 11763,06 8954,08 12219,56 7956,63 3,88 0,450 
FFM (g) 21907,56 11431 22497,72 10528,71 2,69 0,237 
BMD (g/cm2) 60,03 251,06 57,09 238,56 -4,89 0,331 
BMC (g/cm) 1261,78 796,49 1353,11 742,56 7,24 0,705 
Torso/Intero 0,37 0,06 0,38 0,07 2,70 0,523 
Gambe/intero 0,42 0,05 0,42 0,06 0 0,935 
Arti/Torso 1,39 0,40 1,44 0,38 3,59 0,58 
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None statistical difference was found regarding visceral and subcutaneous abdominal 
fat after 12 months of KD. The ratio VAT/SAT was significantly different higher after 
KD (Table 3). 
 
Table 2. Ultrasound assessment of subcutaneous and visceral fat. All data are 
expressed as means ± SD.  
  Preintervention Postintervention %Change P 
value 
 Mean SD Mean SD    
Ultrasound assessment       
Subcutaneous adipose tissue 
(SAT) (cm) 
1,09 1,15 0,93 0,62 -14,68 0,592 
Visceral adipose tissue (VAT) 
(cm) 
2,52 1,31 3,42 1,35 35,71 0,076 
VAT/SAT 3,46 2,51 5,53 4,53 59,82 0,007 
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We analyzed separately postpubertal patients and we didn't detected  difference in 
term of SAT, VAT, ratio VAT/SAT; in prepubertal patients we found a trend of 
increment of VAT and a statistical significance of VAT/SAT ratio; SAT didn't differ 
before and after KD.  
 
Table 3. Ultrasound assessment of subcutaneous and visceral fat in postpubertal 
children. All data are expressed as means ± SD.  
  Preintervention Postintervention %Change P 
value 
 Mean SD Mean SD    
Ultrasound assessment       
Subcutaneous adipose tissue 
(SAT) (cm) 
1,62 1,44 1,1 0,45 -47,27 0,326 
Visceral adipose tissue (VAT) 
(cm) 
3,08 1,25 3,49 1,59 13,31 0,590 
VAT/SAT 2,63 1,53 3,42 1,36 30,03 0,261 
 
Table 4. Ultrasound assessment of subcutaneous and visceral fat in prepubertal 
children. All data are expressed as means ± SD.  
  Preintervention Postintervention %Change P 
value 
 Mean SD Mean SD    
Ultrasound assessment       
Subcutaneous adipose tissue 
(SAT) (cm) 
0,56 0,34 0,76 0,75 35,71 0,45 
Visceral adipose tissue (VAT) 
(cm) 
1,96 1,18 3,35 1,15 70,91 0,05 
VAT/SAT 4,3 3,07 7,6 5,63 76,74 0,001 
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Regarding lipid profile we found any difference after 12 weeks of KD  in term of total 
cholesterol, HDL cholesterol, triglyceride and LDL values. Fasting glucose values were 
unchanged (Table 3).  
 
We classified our patients by using the definitions of the NCEP pediatric panel, in 
order to assess the proportion of patients who developed any form of dyslipidemia: for 
total cholesterol high values were > 200 mg/dl; intermediate between 170-199 mg/dl 
and low values were < 170 mg/dl; for LDL cholesterol high values were > 130 mg/dl; 
intermediate between 110-129 mg/dl and low values were < 110 mg/dl; for HDL  
cholesterol low values were < 35 mg/dl, intermediate between 35-45 mg/dl and high 
values were > 45 mg/dl. For total triglycerides the population was divided in two 
groups according to age: in children < 9 years old high values were > 100 mg/dl; 
intermediate between 75-99 mg/dl and low values were < 75 mg/dl; in children > 9 
years old high values were > 130 mg/dl; intermediate between 90-129 mg/dl and low 
values were < 90 mg/dl.  
 
We analyzed separately these data with chi square test, and we confirmed the absence 
of significant difference between the relative frequences of blood lips before and after 
KD (p=0 for HDL and for both the age class for triglycerides; p=0,169 for total 
cholesterol and p=0,574 for LDL). 
 
Insulin and HOMA, insulin resistance index (values available only for 7 patients), were 
significantly reduced.  
Renal function parameters (BUN, creatinine) and hepatic test (GOT, GPT) were 
unchanged; γGT was slightly reduced after 12 months of KD but the values were 
available only for 13 patients. 
 
Daily REE was unchanged after 12 months of KD, instead the RQ was significantly 
lower, to confirm the complete oxidation of fat (Table 3).  
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Table 3. Metabolic and calorimetric assessment. All data are expressed as means ± 
SD. HOMA-IR, homeostatic model assessment for insulin resistance; QUICKI, 
quantitative insulin sensitivity check index 
  Preintervention Postintervention %Change P 
value 
 Mean SD Mean SD    
Metabolic Parameters            
Blood glucose, mg/dl 73 9,2 72,29 7,7 -0,97 0,830 
Insulin, μU/ml 5,25 2,93 3,06 1,91 -41,71 0,003 
HOMA-IR 1,03 0,65 0,55 0,38 -46,6 0,01 
Triglycerides, mg/dl 70,79 26,03 73,19 28,05 3,39 0,669 
Total cholesterol, mg/dl 180,63 35,05 168,88 17,6 -6,50 0,166 
LDL cholesterol, mg/dl 103,14 24,32 103,35 17,09 0,20 0,932 
HDL cholesterol, mg/dl 54,31 11,72 55,53 14,02 2,25 0,743 
γGT (U/L) 23,05 19,61 16,95 8,87 -26,46 0,034 
GOT (U/L) 23,43 8,89 23,29 6,24 -0,59 0,984 
GPT (U/L) 25,64 26,65 20,74 9,47 -19,11 0,510 
Uric acid (mg/dL) 5,03 1,41 5,29 1,01 5,17 0,444 
Calorimetric measurements       
RQ 0,81 0,06 0,75 0,04 -7,41 0,004 
REE/day (Kcal/day) 1015,11 326,59 1106,53 268,41 9,00 0,051 
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5.2 Results of Aim #2 
 
Characteristics of our sample of patients (sex, age at baseline, neurological disease, 
pharmacological treatment and KD plan) are summarized in Table 4. 
 
Table 4. Characteristics of the sample of patients. 
  Sex Neurological disease Age 
(years) 
B.E. Female Drug-resistant epilepsy 10,1 
B.S. Female GLUT-1 deficiency 1,9 
P.V. Female Drug-resistant epilepsy 3,5 
P.N. Male GLUT-1 deficiency 6,1 
C.F. Female Drug-resistant epilepsy 3,9 
C.A. Male  GLUT-1 deficiency 12 
B. A. Female GLUT-1 deficiency 6,8 
G.N. Male  GLUT-1 deficiency 7,7 
B.R.W. Female GLUT-1 deficiency 6,6 
M.A. Male  GLUT-1 deficiency 10,6 
P.C. Female GLUT-1 deficiency 9,8 
L.C.E.A. Female GLUT-1 deficiency 15,6 
M. I. Male GLUT-1 deficiency 36,8 
C.E. Female GLUT-1 deficiency 8,8 
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The levels of inflammatory markers (high sensitivity C-reactive protein (hs-CRP), 
interleukin-6 (IL-6), adiponectin) were unchanged between and after KD (Table 5). 
FFA levels were unchanged between and after KD. 
We didn’t found any significant increase in ghrelin concentration. 
 
Table 5. Inflammatory markers and adipokines in the sample of patients. All data 
are expressed as means ± SD.  
  Preintervention Postinterventio
n 
%Change P value 
 Mean SD Mean SD    
FFA (mM/siero) 0,59 0,26 0,79 0,19 33,89 0,074 
CRP (mg/l) 1,38 4,26 1,84 3,05 33,33 0,72 
IL 6 (pg/ml) 1,98 0,65 2,34 1,33 18,18 0,217 
TNF α (pg/ml) 0,35 0,92 0,62 1,17 77,14 0,566 
Adiponectine (ug/ml) 38,65 44,11 33,45 19,02 -13,45 0,417 
Leptine (ng/ml) 13,8 18,37 7,29 7,17 -47,17 0,237 
Ghrelin (pg/ml) 391,66 227,37 331,59 157,88 -15,33 0,408 
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6 DISCUSSION 
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6.1 Discussion of Aim#1 
 
In animal model some authors found decreased body weight in rats fed with KD 
(Ziegler et al, 2002; Ribeiro et al, 2008). In contrast to this decreased body weight gain, 
it has been observed (Ribeiro L et al., 2008) an increment in white adipose tissue 
(epididymal plus perirenal fat mass weight) and a clear change in the glucose tolerance 
in animals fed with KD, possibly resulting from insulin resistance. In a very recent 
study (Bielohuby et al, 2013) as well as in previous studies, isoenergetic feeding of the 
Atkins style and the KD resulted in a significant accumulation of visceral fat mass in 
rats compared with chow controls and they confirm that rats fed LC-HF diets exhibit 
impaired glucose tolerance and insulin resistance associated with lower pancreatic  cell 
volumes, despite showing reduced glucose and insulin levels  Adjusting visceral fat 
mass in LC-HF groups to that of controls by reducing the intake of LC-HF diets to 80% 
of the pair-fed groups did not prevent glucose intolerance. 
Concerning body weight and growth in children, only few studies were performed to 
study the effect of KD on nutritional status and their results are controversial. Some 
authors found inadequate growth children under KD in a short term period, with both 
weight and height compromised  (Vining et al, 2002; Liu et al, 2003; Neal et al, 2008; 
Peterson S et al, 2005); in contrast other authors (Tagliabue A, Bertoli S. et al, 2012;  
Couch et al, 1999) found that children were able to maintain linear growth and weight 
percentiles after 6 months on the ketogenic diet. 
In a very recent study evaluating long term period of KD (5 years in GLUT 1 patients) 
authors didn't found any change in both weight and height; none adverse effect was 
detected also in bone mineralization after 5 years of KD.  
No previous studies were performed to study fat accumulation (visceral or other) in 
children treated with KD. This last issue is very important because the increment of 
central fat is particularly damaging because of  it is the well-known link with glucose 
and lipid metabolism conducing to greater risk for diabetes, cardiovascular disease, 
hypertension, and certain cancers and because most children must continue KD for a 
long time.  
 
Our data demonstrate that the ketogenic diet doesn't alter body composition and 
growth in children: in fact we have not revealed differences after 12 moths of KD in 
terms of anthropometric data (weight, height, BMI, waist circumference, waist/height 
ratio).  
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We found any short term modifications concerning skinfold thickness measurements: 
according to previous data in short term (Tagliabue A, Bertoli S. et al, 2012;  Couch et 
al, 1999) and in long term (Bertoli et al, 2013). This finding is reassuring for the safety 
of KD prolonged for several months; however a strict follow up is necessary 
particularly in younger children. 
 
Anthropometric data are also confirmed by analysis of body composition performed 
by DXA: particularly we didn't found increase of fat mass or decrease of lean mass in 
patients after 12 months of KD. We confirm that KD doesn't affect the bone health. 
 
Our patients don’t show at ultrasound evaluation an accumulation of subcutaneous 
adipose tissue (SAT) or visceral adipose tissue (VAT). The fat accumulation has been 
observed in rats, in which it has been observed an increment in epididymal plus 
perirenal fat mass weight (WAT) with WAT weight to body weight ratio in KD-fed rats 
2.4 x higher and constant during 6 week of KD.   
Howewer, in our sample we observed an increment of VAT/SAT ratio suggesting 
changes in abdominal body fat distribution in 2 directions according to age of patients. 
In fact, we analyze separately postpubertal patients and we didn't detected  difference 
in term of SAT, VAT, ratio VAT/SAT; in prepubertal patients we found a trend of 
increment of VAT and a statistical significance of VAT/SAT ratio; SAT didn't differ 
before and after KD.  
 
We considered KD an unique model to study in humans the effect of high fat diet on 
regional adiposity and glucose metabolism and to evaluate the “overflow hypothesis” 
proposed by Bergman et al (Obesity. 2006;14:16S-19S) about the development of 
visceral adiposity, hyperinsulinemia, and insulin resistance after isocaloric high fat diet 
in the dog model: extremely lean individuals are insulin sensitive at the liver and in 
muscle tissue; increasing fat in the diet is proposed to store visceral and subcutaneous 
fat, but the liver is exquisitely sensitive to fat in the visceral depot, leading to hepatic 
insulin resistance primarily (i.e., effect of physiological insulin to suppress glucose 
output) that is observed with moderate visceral adiposity; further fat intake results in 
systemic (i.e., muscle) insulin resistance associated with fat deposition in the 
subcutaneous tissues (Bertoli S, Battezzati A, Giulini Neri I et al , 2013).  
In our study we found that increasing fat in the diet without achieving an hypercaloric 
intake did not increase visceral and subcutaneous abdominal fat and did not cause 
peripheral insulin resistance in children after 12 months of KD, unlike the dog model 
do. Perhaps the dog model isn’t the best to evaluate the effect of isocaloric high fat diet 
in humans. 
 
Resting energy expenditure represents the largest fraction (50-70%) of an individual’s 
total daily energy expenditure. 
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We evaluated the REE and we didn’t find any significant changes. These data are in 
line with our previous 6-month prospective, single-arm observational study designed 
to assess the effects of the KD on the nutritional status, resting energy expenditure 
(REE), and substrate oxidation in 18 patients with drug-resistant epilepsy.  
As expected, fat oxidation increased as an adaptation to the high fat and low 
carbohydrate intakes typical of the KD. In fact the respiratory quotient decreased 
significantly, as effect by the diet (complete fat oxidation). 
Interestingly, Tagliabue et al found that the increase in fat oxidation was the main 
independent predictor of the reduction in seizure frequency suggesting that certain fat 
oxidation products may be directly or indirectly involved in the reduction of seizure 
frequency induced by the KD.  
In this regard, an experimental study by Harney et al has shown that acute inhibition 
of fatty acid oxidation in KD-fed animals resulted in a shorter latency to 
experimentally-induced seizures, which was accompanied with a drop in plasma b-
hydroxybutyrate levels. 
 
It has long been known that KD can present several side effect regarding metabolic 
parameters. 
 
Among them dyslipidemia was described. Literature data (Groesbeck et al, 2006) noted 
an initial (over 6 months) increase of  total cholesterol and triglycerides and a gradual 
return towards baseline values over 2 years. These alteration  may not have short term 
effects, but the long term relevance of this finding is unknown over the lifetime of a 
patient (Kwiterovich et al., 2003). Lipid metabolism in our patients was unchanged 
before and after KD. 
We classified our patients by using the definitions of the NCEP pediatric panel, in 
order to assess the proportion of patients who developed any form of dyslipidemia.  
At baseline, total cholesterol mean levels were in the borderline-high range but they 
returned in an acceptable range after 12 months of KD (trend without statistical 
significance). LDL, HDL and triglycerides mean levels remained in an acceptable range 
before and after diet.  
We analyzed separately these data with chi square test, and we confirmed the absence 
of significant difference between the relative frequences of blood lips before and after 
KD (p=0 for HDL and for both the age class for triglycerides; p=0,169 for total 
cholesterol and p=0,574 for LDL). 
 
These finding demonstrate that KD is probably safe on the short/medium term, by 
maintaining lipid profiles as at baseline. However, a strict nutritional follow up is 
suggested to evaluate and control the eventual onset of dyslipidemia in treated 
patients.  
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Impaired glucose tolerance and insulin resistance were described in some animal 
models of KD. Our patients didn't show any change in glucose values and a significant 
decrease of insulin and HOMA values after KD but we didn't perform dynamic test to 
assess the insulin sensitivity. 
The only data available in literature about this issues in children are on GLUT1 
patients (Rauchenzauner M et al, 2008): the authors found significantly lower serum 
insulin concentrations and HOMA-IR versus controls; this data probably reflect the 
reduced carbohydrate intake on a KD. Further study are necessary to clarify this 
finding and its reversibility. Of note, similar fasting glucose concentrations in both 
groups do not support the perception of hypoglycemic risk during long-term KD. 
 
Hyperuricemia and develoment of renal stones are described durine KD. In our 
patients the uric acid levels didn't increase afetr 12 months of KD and none of patients 
developed stones. 
 
Finally, the hepatic transaminases were normal, and we registered a slight reduction of 
γGT: these data are  comforting for the liver function in the long term in spite of high 
intake of fat during KD. 
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6.2 Discussion of Aim#2. Adipocytokines and markers of inflammation 
 
Metabolic syndrome (MS) describes the clustering of abdominal obesity, lipid 
abnormalities, hypertension, and hyperglycemia. It is a strong independent contributor 
to the onset of type 2 diabetes and cardiovascular disease.  
Subjects suffering from MS may have a higher inflammation status and a higher level 
of oxidative stress. A higher inflammation status was significantly correlated with 
decreases in the levels of antioxidant enzymes and adiponectin and an increase in the 
risk of MS. 
Metabolic adverse effects of a long-term KD in patients requiring KD for several years 
(eg, GLUT1 deficiency patients) are of concern due to the possible higher 
cardiovascular risk in these patients later in life. 
Therefore, we performed a measurements of appropriate biomarkers of inflammatory 
status at baseline and after a short period (12 weeks) of KD period in a sample of 
patients starting KD. 
High sensitivity C-reactive protein (hsCRP) is a marker of systemic inflammation 
which has been known to be related to cardiovascular disease risk factors such as 
obesity, high blood pressure, apolipoprotein B and fibrinogen and is also known to 
impair insulin signaling. 
TNF-α is a most representative pro-inflammatory cytokine which is produced mainly 
by macrophages and lymphocytes. 
IL-6 is another pro-inflammatory cytokine related to insulin resistance and has also 
been shown to facilitate the hepatic production of hsCRP 
Adiponectin is the most abundant adipokine in circulation and it exerts anti-
inflammatory activity; it has been demonstrated that adiponectin modulates insulin 
sensitivity by stimulating glucose utilization and fatty acid oxidation via 
phosphorylation and activation of AMPK in muscle and liver; adiponectin also 
possesses vasculo-protective effects which are mediated by promoting vasodilatation 
and vascular repair, and inhibiting ROS formation, macrophage activation and smooth 
muscle cell proliferation.  
Devaraj and colleagues reported that low adiponectin was the strongest predictor of 
MS (OR, 2.5; 95% CI, 1.3-4.5). 
It has been stated that a higher level of hs-CRP or IL-6 or a lower level of adiponectin  
were associated with a significantly greater risk of metabolic syndrome.  
The levels of inflammatory markers (hs-CRP, IL-6, adiponectin) were unchanged in 
our sample of patients after 12 weeks of KD. The absence of change in inflammatory 
markers levels should confirm that with KD treatment we don't detect signals of risk of 
metabolic syndrome and cardiovascular disease despite high fat intake. 
 
Leptin levels were unchanged after 12 weeks of KD. Since leptin levels are strongly 
associated with the amount of adipose tissue (Toussirot E et al, 2013) we determined 
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leptin corrected for fat mass and we didn't found any statistical difference before and 
after KD (p=0,213). 
Leptin is a well-known pro-inflammatory marker, and this low concentration in 
patient on KD is consistent with the full panel of inflammatory markers in these 
patients. 
Leptin has been investigated also for a possible role in the anticonvulsivant action of 
the KD. Our data are in line with the unique study performed on children treated with 
KD (and particularly prepubertal children with GLUT1DS). The authors found leptin  
concentrations lower in patients on KD compared with control subjects, and a 
significant positive correlations of leptin with fasting serum insulin concentrations, 
glucose levels, HOMA-IR. In control subjects, no correlations between adipocytokines 
and markers of obesity or IR were seen. They postulate that low body fat mass was due 
to low leptin and high sOB-R concentrations. Nevertheless, low levels of leptin are in 
contrast to increased leptin concentrations recently observed in young rats on a KD. 
The increase in serum leptin may contribute to the ketogenic diet’s anticonvulsant 
effect because leptin has anticonvulsant properties in several in vitro and in vivo 
models. Like leptin, insulin can regulate neuronal excitability by modulating multiple 
ion channels. Therefore, the potential mechanism of increased leptin levels 
contributing to the anticonvulsant effect of a KD appears to be unlikely in children 
with Glut1DS.
 
FFA levels were unchanged between and after KD.  In KD-fed animals, an elevated 
flux of FFAs must occur which is not necessarily accompanied by the dyslipidemia 
observed in metabolic syndrome. The visceral lipogenesis in rats was supported by an 
increment in adipocyte PEPCK, aiming to provide glycerol 3-phosphate to 
triacylglycerol synthesis and this fat accumulation was accompanied by glucose 
intolerance. These data contribute to our understanding of the metabolic effects of the 
KD in adipose tissue and liver in rats, but they shouldn’t be confirmed in human 
studies.  
Moreover in Bergman hypothesis FFAs themselves are responsible for the insulin 
resistance of the liver, at least with moderate increases in fat intake, and this data 
confirm the great differences between dog and human models. 
 
We didn’t found any significant increase in ghrelin concentration, as previous 
observed (Epilepsy Research (2012) 100, 245—251 Hypothalamic hormones and 
metabolism, Liu Lin Thio);  ghrelin has only very recently been introduced into the 
field of epilepsy, and has already led to contradictory clinical publications.  
Experiments in rodents showed that the ketogenic diet did not alter galanin and NPY 
mRNA expression (Tabb et al., 2004) or plasma ghrelin levels (Honors et al., 2009). 
Weinshenker reflects that the absence of neuropeptide changes does not necessarily 
rule out a contribution of orexigenic neuropeptides to the anticonvulsant effect of the 
 68 
 
KD. One possibility could be that the effect of KD on these neuropeptides becomes 
evident following seizure activity. This is where ghrelin differs from galanin and NPY 
because, although ghrelin levels appear to decrease following seizure activity, the 
opposite takes place for NPY and galanin. 
It seems that the anticonvulsant effect by the KD is not linked to ghrelin levels: 
therefore, it is of interest that these orexigenic neuropeptides are further investigated 
to elucidate whether or not there is indeed a link between their anticonvulsant 
potential and the ketogenic diet.  
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